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Cancer cells show alterations in metabolism that
support malignancy and disease progression. Prom-
inent among thesemetabolic changes is elevations in
neutral ether lipids (NELs).Wehave previously shown
that the hydrolytic enzymeKIAA1363 (or AADACL1) is
highly elevated in aggressive cancer cells, where it
plays a key role in generating the monoalkylglycerol
ether (MAGE) class of NELs. Here, we use activity-
based protein profiling-guided medicinal chemistry
to discover a highly potent and selective inhibitor of
KIAA1363, the carbamate JW480. We show that
JW480, and an shRNA probe that targets KIAA1363,
reduce MAGEs and impair the migration, invasion,
survival, and in vivo tumor growth of human prostate
cancer cell lines. These findings indicate that the
KIAA1363-MAGE pathway is important for prostate
cancer pathogenesis and designate JW480 as
a versatile pharmacological probe for disrupting this
pro-tumorigenic metabolic pathway.
INTRODUCTION
For more than 40 years, it has been known that tumor cells show
dramatic elevations in their neutral ether lipid (NEL) content.
Seminal work by Snyder and Wood in the 1960s first reported
that rodent and human tumors possess significantly higher levels
of NELs relative to normal tissue (Snyder andWood, 1969; Wood
and Snyder, 1967). Over the ensuing decades, this finding has
been confirmed for a wide range of cancer cells and primary
tumors from several tissues of origin (Albert and Anderson,
1977; Lin et al., 1978; Roos and Choppin, 1984). Provocative
evidence has also emerged to suggest a pro-tumorigenic func-
tion for NELs, including a study where the levels of these lipids
were found to correlate closelywith tumorigenicity across apanel
of mouse fibroblast cell lines (Roos and Choppin, 1984). None-
theless, whether elevated NELs are causally linked or merely
associated with cancer has remained unclear. Moreover, the
enzymes responsible for regulating NEL metabolism in cancer
cells are, for the most part, poorly understood.
We have recently determined that the previously uncharacter-
ized transmembrane enzyme KIAA1363 (also called AADACL1)
controls the production of the monoalkylglycerol ether (MAGE)476 Chemistry & Biology 18, 476–484, April 22, 2011 ª2011 Elsevierclass of NELs in cancer cells (Chiang et al., 2006). KIAA1363
acts as a 2-acetyl MAGE hydrolase (Chiang et al., 2006) and is
likely the principal source for this activity in tumor cells, which
was originally detected by Snyder’s group in the early 1990s
(Blank et al., 1990). MAGEs can be further converted by cancer
cells into the bioactive lysophospholipids alkyl-lysophosphatidyl
choline (alkyl-LPC) and alkyl-lysophosphatidic acid (alkyl-LPA)
(Chiang et al., 2006). Stable knockdown of KIAA1363 expression
impaired tumor cell migration and tumor growth in vivo, suggest-
ing a potentially key role for this enzyme in promoting cancer
pathogenesis. Consistent with this premise, we, and others,
have found that KIAA1363 is highly elevated in aggressive
breast, melanoma, ovarian (Chiang et al., 2006; Jessani et al.,
2002), and pancreatic (Iacobuzio-Donahue et al., 2002) cancer
cells, as well as primary breast (Ferguson et al., 2005; Jessani
et al., 2005) and ovarian (Haverty et al., 2009) tumors.
Although the aforementioned discoveries suggest that
KIAA1363 could represent an interesting pharmacological target
for impairing cancer malignancy, selective inhibitors for this
enzyme are lacking. Here, we report the results of an activity-
based protein profiling (ABPP)–guided (Berger et al., 2004;
Cravatt et al., 2008; Liu et al., 1999) medicinal chemistry study
aimed at optimizing inhibitors for KIAA1363. This effort identified
an O-aryl carbamate JW480 that acts as a potent and selective
inhibitor of KIAA1363. JW480 is orally active and capable of fully
inhibiting KIAA1363 in mice for at least 24 hr following a single
administration. We show that JW480, as well as an shRNA probe
that targets KIAA1363, reduce MAGE levels in human prostate
cancer cells and impair their migration, invasion, survival, and
in vivo tumor growth.
RESULTS
Aggressive Human Prostate Cancer Cells Show High
Levels of KIAA1363 Activity
In previous ABPP studies, we found that KIAA1363 activity
was elevated in aggressive humanbreast,melanoma, andovarian
cancer cells (Chiang et al., 2006; Jessani et al., 2002), as well as
primary human breast tumors (Jessani et al., 2005). Here, we
analyzed a panel of human prostate cancer cell lines by ABPP
using the serine hydrolase–directed activity-based probe fluoro-
phosphonate-rhodamine (Jessani et al., 2002; Patricelli et al.,
2001) and observed that KIAA1363 activity, detectable as
a 45 kDa FP-rhodamine-reactive doublet (Figure 1A), was
muchhigher in theandrogen-independent humanprostatecancer
lines PC3 and DU145 compared with the androgen-dependentLtd All rights reserved
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Figure 1. KIAA1363 IsElevated inAndrogen-
Independent Human Prostate Cancer Cell
Lines
(A) ABPP of serine hydrolase activities in the
androgen-dependent LNCaP and androgen-
independent PC3 and DU145 cell lines. Serine
hydrolase activities were labeled in whole-cell
proteomes with the activity-based probe
FP-rhodamine (1 mM, 30 min) (Jessani et al., 2002;
Patricelli et al., 2001) and were detected by
SDS-PAGE and in-gel fluorescence scanning
(fluorescent gel shown in grayscale). KIAA1363
activity is much higher in PC3 and DU145 cells
compared to LNCaP cells. Note that KIAA1363
migrates as two distinct glycoforms in cancer
cells, as described previously (Chiang et al., 2006;
Jessani et al., 2002).
(B) PC3 and DU145 cells also show much higher
2-acetyl MAGE hydrolytic activity compared
to LNCaP cells. Note that virtually all 2-acetyl
MAGE hydrolase activity in prostate cancer cells is
eliminated by the KIAA1363 inhibitor AS115
(10 mM, 4 hr treatment, in situ).
(C and D) PC3 and DU145 cells show elevated migratory (C) and invasive (D) activity compared to LNCaP cells.
(E) PC3 and DU145 cells have much higher levels of MAGEs (C16:0, 1-O-palmityl MAGE; C18:0, 1-O-stearyl MAGE; C18:1 1-O-oleyl MAGE) compared to
LNCaP cells. **p < 0.01 for comparisons between PC3 and DU145 cells versus LNCaP cells. Data are presented as means ± standard error of the mean (SEM);
n = 4–5/group.
Chemistry & Biology
Selective Inhibitor for Cancer Hydrolase KIAA1363human prostate cancer line LNCaP (Figures 1A and B). This
difference in activity was also detected using the KIAA1363
substrate 2-acetyl MAGE (Figure 1B). PC3 and DU145 cells
showed much greater migratory (Figure 1C) and invasive
(Figure 1D) activity compared with LNCaP cells, consistent with
the reported differences in aggressiveness among these cancer
lines (Hoosein et al., 1991). Finally, PC3 and DU145 cells
possessed higher levels of the KIAA1363-regulated NELs C16:0,
C18:0, and C18:1 MAGE compared to LNCaP cells (Figure 1E).
These data, together, indicate that aggressive prostate cancer
cells contain a hyperactive KIAA1363-MAGE pathway.
Development of JW480, a Potent, Selective,
and In Vivo Active KIAA1363 Inhibitor
We next wanted to examine the function of KIAA1363 in prostate
cancer cells. Although lead inhibitors, such as trifluoromethyl
ketones (Leung et al., 2003) and the carbamate AS115 (Chiang
et al., 2006) (Figure 2A), have been created for KIAA1363, these
reagents lack the desired combination of selectivity and in vivo
activity suitable for extensive biological studies. In a recent
large-scale screen (Bachovchin et al., 2010), we discovered
a new structural class of carbamates, representative members
of which include WWL38 and JW148 (Figure 2A), that inhibited
KIAA1363 with good selectivity compared with common off-
target enzymes such as fatty acid amide hydrolase (FAAH), as
judged by gel-based competitive ABPP of a mouse brain
proteome (Figure 2B). This enhanced selectivity appeared to be
imparted by the O-2,3-dihydrobenzofuran leaving group, which
is well-tolerated by KIAA1363 but not most other serine hydro-
lases (see Figure S1 and Table S1 available online). However,
WWL38 and JW148 showed only moderate potency for
KIAA1363 (IC50 values, 200 nM) and still exhibited cross-reac-
tivitywith twoother serine hydrolases—hormone-sensitive lipase
(HSL) (Figure 2C) and acetylcholinesterase (AChE) (Figure 2D).Chemistry & Biology 18,We sought to enhance the potency and selectivity of these lead
carbamates through ABPP-guided medicinal chemistry.
We noted that replacing the O-2,3-dihydrobenzofuran group
of WWL38 and JW148 with an O-2-isopropylphenyl leaving
group created a carbamate JW464 (Figure 2A) with much
improved potency for KIAA1363 (Figure 2B), but which still
showed cross-reactivity with AChE (Figure S2). On the other
hand, O-aryl carbamates with a bulkier N-ethylnaphthalene
substituent, such as JW440 (Figure 2B), showed little or no
activity against AChE or HSL (Figure S2), while maintaining
good potency for KIAA1363 (Figure 2B). Combining these
two structural features engendered a carbamate JW480 that
inhibited mouse brain KIAA1363 with exceptional potency (IC50
value, 20 nM; Figures 2B and 2D), while showing negligible
cross-reactivity with HSL (Figure 2C), AChE (Figure 2D), or other
mouse brain serine hydrolases (Figure 2B).
We next confirmed that JW480 also inhibited human
KIAA1363 in PC3 cell proteomes (in vitro treatment), showing
an IC50 value of 12 nM in competitive ABPP assays (Figure 3A).
Similar inhibition was observed in living PC3 cells in the presence
or absence of 10% fetal calf serum (in situ treatment), where
JW480 inactivated KIAA1363 with IC50 values of 6–12 nM (Fig-
ure 3B; Figure S3). We also confirmed inhibition of KIAA1363
by JW480 using a 2-acetyl MAGE substrate assay (Figure S3).
The in situ inhibition of KIAA1363 by JW480 (1 mM) was main-
tained for at least 48 hr (Figure S3). JW480 showed excellent
selectivity for KIAA1363 in PC3 cells (Figures 3A and 3B), as
well as in DU145 and LNCaP cells (Figure S3), as judged by
gel-based competitive ABPP. This selectivity was confirmed by
competitive ABPP-MudPIT (Li et al., 2007; Long et al., 2009a),
a mass-spectrometry–based method that displays higher reso-
lution than gel-based ABPP and revealed no off-target activity
for JW480 (1 mM in situ treatment, 4 hr) across the >30 serine
hydrolase activities detected in PC3 cells (Figure 3C).476–484, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 477
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Figure 2. Development of JW480, a Potent
and Selective KIAA1363 Inhibitor
(A) Structures of various KIAA1363 inhibitors,
including first-generation inhibitors, such as
AS115, WWL38, and JW148, along with second-
generation inhibitors JW440 and JW464, which
showed improved selectivity and potency for
KIAA1363, respectively. Combining key structural
features of JW440 and JW464 (boxed) provided
JW480, which showed improved potency and
selectivity for KIAA1363.
(B) The left panel shows a competitive ABPP gel for
various KIAA1363 inhibitors with the mouse brain
membrane proteome (10 mM inhibitor concentra-
tion). Note that AS115, but not other agents, also
inhibits FAAH. The right panel shows concentra-
tion-dependent inhibition of KIAA1363 in mouse
brain proteome.
(C) Competitive ABPP gels comparing the activity
of KIAA1363 inhibitors against the common off-
target enzymes HSL and FAAH. HSL activity
was measured in a rosiglitazone-differentiated
3T3-10T1/2 adipocyte proteome, whereas FAAH
activity was measured in mouse brain proteome.
(D) Concentration-dependent inhibition of AChE
and KIAA1363 by JW148 and JW480. KIAA1363
activity was measured by competitive ABPP in
a mouse brain proteome. AChE activity was
measured in a mouse brain proteome using the
substrate acetylthiocholine (Ellman et al., 1961)
because this enzyme is too low in abundance for
detection by gel-based ABPP. Note, however, that
AChE activity can be measured by competitive ABPP-MudPIT (see Figure 4C), which confirmed negligible cross-reactivity for JW480 with this enzyme. The
following IC50 values, also shown in the figure, were measured: JW148, IC50 for KIAA1363 of 0.2 mM (95% confidence limit, 0.1–0.3 mM); IC50 for AChE of 1 mM
(1.09–1.3 mM); JW480 IC50 for KIAA1363 of 0.02 mM (0.021–0.025 mM); IC50 for AChE >100 mM. Gels are representative images from n = 3; Data in (D) are
presented as means ± standard error of the mean (SEM); n = 3/group.
See also Table S1 and Figures S1 and S2.
Chemistry & Biology
Selective Inhibitor for Cancer Hydrolase KIAA1363We next asked whether JW480 could inhibit KIAA1363
in vivo by treating mice with varying quantities of this inhibitor
(1–80 mg/kg, i.p. or oral administration, 4 hr) and then sacrificing
the animals and analyzing their brain proteomes by competitive
ABPP. JW480 proved to be highly active in vivo, showing
complete inhibition of brain KIAA1363 at doses of 5 and
20 mg/kg following i.p. (Figure 4A) and oral (Figure 4B) routes
of administration, respectively. As was observed in PC3 cells,
JW480 showed excellent selectivity for KIAA1363 in brain pro-
teomes from inhibitor-treated mice as judged by gel-based
competitive ABPP (Figures 4A and 4B). This selectivity was
confirmed by competitive ABPP-MudPIT, where only a single
off-target was observed among the 30 serine hydrolase activ-
ities detected in the brain proteome—the carboxylesterase ES1
(Figure 4C). ES1 is not expressed in the brain (Krishnasamy et al.,
1998), but rather likely originates from contaminating blood in the
brain tissue preparation; this enzyme is secreted into the blood
by the liver (Krishnasamy et al., 1998). The selectivity profile of
JW480 thus matches those of other carbamate inhibitors of
serine hydrolases, such as the FAAH inhibitor URB597 (Kathuria
et al., 2003) or the monoacylglycerol lipase inhibitor JZL184
(Long et al., 2009a), which also show excellent specificity for
their target enzymes with the exception of some cross-reactivity
with carboxylesterases (Alexander and Cravatt, 2005; Long
et al., 2009b). Finally, time course studies confirmed that inhibi-478 Chemistry & Biology 18, 476–484, April 22, 2011 ª2011 Elseviertion of KIAA1363 was maintained in vivo for up to 24 hr following
a single administration of JW480 (20 mg/kg, oral; Figure 4C,
inset).
These data taken together indicate that JW480 is a potent and
selective inhibitor of both human and mouse KIAA1363 that can
be used to inactivate this enzyme in living cells or animals.
JW480 Lowers MAGEs and Impairs Pathogenicity
of Prostate Cancer Cells
We next tested the effects of JW480 on the KIAA1363-MAGE
pathway in prostate cancer cells. JW480 treatment (1 mM)
completely blocked 2-acetyl MAGE hydrolase activity (Figures
5A and 5C) and caused significant reductions in MAGE lipids
(Figures 5B and 5D) in both PC3 (Figure 5B) and DU145 (Fig-
ure 5D) cells. Similar effects were observed in PC3 cells where
KIAA1363 was stably knocked down by a small hairpin (sh)
RNA (shKIAA1363 cells; Figures 5E and 5F). Other KIAA1363
inhibitors, such as AS115 and JW148, but not the FAAH inhibitor
URB597, also caused reductions in MAGE lipids in prostate
cancer cells (Figure S4).
Additional studies provided evidence that the KIAA1363-
MAGE pathway is important for prostate cancer aggressiveness.
For instance, JW480-treated and shKIAA1363 prostate cancer
cells displayed reductions in migration (Figure 6A), invasion (Fig-
ure 6B), and survival in serum-free media (Figure 6C). TheseLtd All rights reserved
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Figure 3. JW480 Selectively Inhibits KIAA1363 in Human Prostate Cancer Cells
(A and B) Gel-based competitive ABPP profiles of proteomes fromPC3 cells treated with a range of concentrations of JW480 in vitro (A) or in situ (B). The following
IC50 values were measured for KIAA1363: in vitro: 0.012 mM (95% confidence limits, 0.009–0.014 mM); in situ: 0.006 mM (0.005–0.007 mM). Note that other serine
hydrolase activities detected by gel-based ABPP were not affected by JW480. Gels are representative images from n = 3.
(C) Competitive ABPP-MudPIT results for PC3 cells treated with JW480 (1 mM, 48 hr). Among the 30 serine hydrolase activities measured by ABPP-MudPIT in
whole PC3 cell proteomes, only KIAA1363 was inhibited by JW480. Only serine hydrolases that showed an average spectral count valueR8 were subjected to
quantitative analysis. **p < 0.01 for JW480- versus DMSO-treated control groups. Data are presented as means ± standard error of the mean (SEM); n = 4/group.
See also Figure S3.
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Selective Inhibitor for Cancer Hydrolase KIAA1363effects were also observed with other KIAA1363 inhibitors
(AS115 and JW148), but not with the FAAH inhibitor URB597
(Figure S5). JW480 did not affect the survival in LNCaP cells,JW480
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Chemistry & Biology 18,which express low levels of KIAA1363 (Figure S5). Finally, we
took advantage of JW480’s exceptional in vivo activity to test
whether pharmacological blockade of KIAA1363 affected PC3oral (20 mg/kg)
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Figure 5. Disruption of KIAA1363 Activity
Reduces MAGE Lipids in Prostate Cancer
Cells
(A and C) JW480 ablates KIAA1363 activity as
assessed by 2-acetyl MAGE hydrolytic activity
(1 mM, 48 h) in PC3 (A) and DU145 (C) cells.
(B and D) JW480 significantly reduces MAGE
levels in PC3 (B) and DU145 (D) (1 mM, 48 hr).
(E) Stable knockdown of KIAA1363 using a short-
hairpin oligonucleotide (shKIAA1363) reduces
KIAA1363 activity by >70% in PC3 cells as as-
sessed by ABPP (left) or 2-acetyl MAGE hydrolytic
activity (right).
(F) shKIAA1363 PC3 cells have significantly
lower levels of MAGEs. **p < 0.01 for JW480-
treated or shKIAA1363 cells compared to their
respective control groups (DMSO-treated and
parental/shControl cells). Data are presented
as means ± standard error of the mean (SEM);
n = 4–5/group.
See also Figure S4.
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Selective Inhibitor for Cancer Hydrolase KIAA1363tumor growth in a mouse xenograft model. We found that PC3
tumor growth was significantly impaired in mice treated daily
with JW480 (80 mg/kg, oral) compared to control mice treated
with vehicle (Figure 7A). We confirmed by competitive ABPP
that KIAA1363 activity was completely ablated in tumors ex-
planted from mice treated with JW480 (Figure 7B). We observed
a similar reduction in tumor growth for shKIAA1363 PC3 cells
compared to control cells (Figure 7C).
These results, taken together, show that pharmacological or
shRNA-mediated disruption of KIAA1363 reduces MAGE levels
and impairs the pathogenic properties of human prostate cancer
cells.
DISCUSSION
Serine hydrolases are an exceptionally large and diverse class of
enzymes that play important roles in virtually all biological
processes in mammals (Simon and Cravatt, 2010). Many serine
hydrolases, however, remain poorly characterized with respect
to their biochemical and physiological functions. Using ABPP,
we previously identified one such serine hydrolase, the integral
membrane enzyme KIAA1363, as being highly expressed by
aggressive human cancer cells (Jessani et al., 2002) and primary
tumors (Jessani et al., 2005). We also succeeded in identifying480 Chemistry & Biology 18, 476–484, April 22, 2011 ª2011 Elsevier Ltd All rights reservedlead inhibitors for KIAA1363, which
helped to define a role for this enzyme in
NEL metabolism in cancer cells (Chiang
et al., 2006). These findings, when inte-
grated with the large historical body of
work designating NEL metabolism as
a prominent biochemical pathway dysre-
gulated in cancer cells (Albert and Ander-
son, 1977; Lin et al., 1978; Roos and
Choppin, 1984; Snyder and Wood,
1969; Wood and Snyder, 1967), suggest
that KIAA1363 might play an important
role in tumorigenesis. Testing this hypoth-esis, however, required more advanced KIAA1363 inhibitors that
possess the potency and selectivity needed for extensive phar-
macological studies.
Here, we have used competitive ABPP-guided medicinal
chemistry to create JW480, a low-nanomolar, selective, and
in vivo–active inhibitor for KIAA1363. We believe that JW480
likely acts as an irreversible inhibitor of KIAA1363 that carbamoy-
lates the enzyme’s serine nucleophile, which is consistent
with the known mechanism of action for other carbamate inhib-
itors of serine hydrolases (Alexander and Cravatt, 2005; Long
et al., 2009b). Confirmation of an irreversible mode of inhibition
for JW480 will require further studies, such as direct mass-spec-
trometry characterization of the carbamoylated inhibitor-enzyme
adduct as has been measured for other serine hydrolases
(Alexander and Cravatt, 2005). However, an irreversible mecha-
nism of action for JW480 is supported by our competitive ABPP
results showing sustained inhibition of KIAA1363 in tissue
extracts from JW480-treated mice. Assuming that JW480 is an
irreversible inhibitor of KIAA1363, future experiments could
include (1) appending an alkyne onto JW480 to convert it into
a ‘‘clickable’’ probe for assessing proteome-wide target interac-
tions beyond the serine hydrolases that are counterscreened by
competitive ABPP, as has been shown for other enzymes (Ahn
et al., 2009; Alexander and Cravatt, 2005), and (2) incorporation
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Figure 6. Disruption of KIAA1363 Activity Impairs Prostate Cancer
Cell Pathogenicity
(A–C) JW480-treated and shKIAA1363 PC3 cells show reduced migration (A),
invasion (B), and serum-free cell survival (C). Cells were treated with JW480
(1 mM, 48 hr in situ) for 48 hr prior to biological measurements. **p < 0.01 for
JW480-treated or shKIAA1363 cells compared to their respective control
groups (DMSO-treated and parental/shControl cells). Data are presented as
means ± standard error of the mean (SEM); n = 4–5/group. See also Figure S5.
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Selective Inhibitor for Cancer Hydrolase KIAA1363of a fluorophore into the JW480 structure for creating a probe to
image KIAA1363 activity in vivo, as has been achieved for other
enzymes (Blum et al., 2005).
The starting scaffold for JW480 originated from a recent
‘‘library-versus-library’’ competitive ABPP screen where we as-
sayed >70 serine hydrolases against >150 carbamate small
molecules (Bachovchin et al., 2010). The breadth of this screen
pointed to areas for improvement of lead KIAA1363 inhibitors,
most notably, in designating HSL and AChE as common off-
targets for these compounds. Interestingly, and as noted previ-
ously (Bachovchin et al., 2010), neither enzyme shares much
sequence homology with KIAA1363, underscoring the value of
proteomic profiling methods like competitive ABPP that can
identify ‘‘pharmacological homology’’ among distantly related
enzymes. We were able to minimize cross-reactivity with HSL
and AChE by incorporating a bulky naphthalene group into the
N-alkyl substituent of JW480.Chemistry & Biology 18,Eliminating AChE cross-reactivity was of obvious importance,
given that potent inhibitors of this enzyme are neurotoxic (Casida
and Quistad, 2005). Removing HSL cross-reactivity may also be
valuable because both KIAA1363 and HSL are expressed at high
levels in macrophages, where each enzyme has been suggested
to play a role in neutral cholesterol ester hydrolysis (Buchebner
et al., 2010; Igarashi et al., 2010; Okazaki et al., 2008). The rela-
tive contribution that KIAA1363 and HSL make to cholesterol
ester metabolism in macrophages remains unclear, and we
anticipate that JW480 should offer a valuable pharmacological
tool to investigate this question. Among the more than 40 serine
hydrolases counterscreened by competitive ABPP in our
combined analyses of brain and cancer cell proteomes, only
a single off-target for JW480 was detected—the carboxylester-
ase ES1. As has been discussed previously (Bachovchin et al.,
2010), CEs are promiscuous enzymes involved in xenobiotic
metabolism in tissues such as the liver. They are common off-
targets for mechanism-based serine hydrolase inhibitors,
including carbamates (Alexander and Cravatt, 2005; Bachovchin
et al., 2010; Long et al., 2009b). We do not believe, however, that
such cross-reactivity with ES1 (and possibly other CEs) is amajor
problem for using JW480 as a pharmacological tool to investi-
gate KIAA1363 function, especially for studies in the nervous
system and cancer, where CE expression is low. Furthermore,
one can use carbamates that do not inhibit KIAA1363, but still
show CE cross-reactivity as ‘‘negative control’’ compounds, as
we have shown in this study with the FAAH inhibitor URB597.
Using JW480 (and an shRNA probe that targets KIAA1363),
we found that disrupting KIAA1363 reduces MAGE levels in
human prostate cancer cells and impairs several of their pro-
tumorigenic properties, including migration, invasion, and
serum-free survival. These metabolic and cell biological effects
were correlated with significant reductions in tumor growth in
mouse xenograft models treated with JW480 (or using
shKIAA1363 prostate cancer cells). These data collectively
support a pro-tumorigenic function for KIAA1363. We should
note, however, that tumors treated with JW480 or from
shKIAA1363 prostate cancer cells continued to grow in vivo,
indicating that blockade of KIAA1363 slows, but does not
completely block, tumor progression. This outcome was not
due to incomplete inhibition of KIAA1363, because we were
able to confirm full inactivation of KIAA1363 in explanted tumors
from JW480-treated mice. In future studies, it would be inter-
esting to test whether KIAA1363 inhibitors show additive or
synergistic antitumor activity when combined with other chemo-
therapeutic agents. Also, the strong anti-invasive effects of
JW480 suggest that blockade of KIAA1363 could impede cancer
metastasis in vivo. Finally, more extensive biochemical and cell
biological studies are required to understand the mechanism
by which KIAA1363-MAGE pathway supports prostate cancer
pathogenicity. Previous work showed that this pathway is
coupled to the production of pro-tumorigenic lipids, such as
alkyl-LPA, in ovarian cancer cells (Chiang et al., 2006). Broader
metabolomic experiments should reveal whether changes in
LPA or other bioactive lipids are also observed in JW480-treated
prostate cancer cells.
In closing, we believe that JW480 possesses an impressive
array of features that qualify it as a frontline pharmacological
probe for KIAA1363, including high potency against both the476–484, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 481
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Figure 7. Disruption of KIAA1363 Activity
Impairs Prostate Tumor Growth In Vivo
(A) JW480 treatment (80 mg/kg, oral gavage, one
dose per day, initiated on the day of tumor cell
implantation) significantly reduces PC3 tumor
xenograft growth in immune-deficient SCID mice.
We used a dose of 80 mg/kg JW480 because we
found that a higher quantity of this compound was
required to completely block KIAA1363 in SCID
mice compared to normal mice (Figure S6).
(B) Tumors from mice treated with JW480,
removed 4 hr after the final administered dose of
JW480 (day 33, part A), show complete loss of
KIAA1363 activity compared to control (vehicle-
treated) tumors as determined by ABPP. Ex vivo treatment with JW148 (10 mM, 30 min) was used to confirm that the upper and lower FP-rhodamine-reactive
bands correspond to KIAA1363, while the middle FP-rhodamine-reactive band is another (JW148-insensitive) serine hydrolase.
(C) shKIAA1363 PC3 cells also show significantly reduce tumor growth compared to parental and shControl PC3 cells in a SCID mouse xenograft model.
**p < 0.01 for JW480-treated or shKIAA1363 cells compared to their respective control groups (vehicle-treated and parental/shControl cells). Data are presented
as means ± standard error of the mean (SEM); n = 6–8/group. See also Figure S6.
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reactivity with other serine hydrolases, and excellent activity in
living cells and mice. We anticipate that future studies with
JW480 will help to illuminate the role that KIAA1363 plays in
many (patho)physiological processes, including cancer, macro-
phage biology, and the nervous system. From a methodological
perspective, our success in converting lead carbamates origi-
nating from a large-scale screen (Bachovchin et al., 2010) into
a KIAA1363 inhibitor that displays greatly improved potency
and selectivity can be attributed, at least in part, to the informa-
tion content garnered by competitive ABPP, which assays
inhibitors against numerous enzymes in parallel directly in native
proteomes. This type of ‘‘proteomic medicinal chemistry,’’ which
has also impacted other inhibitor development programs (Ara-
stu-Kapur et al., 2008; Deu et al., 2010; Li et al., 2007; Long
et al., 2009a; Staub and Sieber, 2009), should continue to
provide an efficient means to create versatile pharmacological
probes for a wide range of enzymes.
SIGNIFICANCE
Mapping dysregulated metabolic pathways in cancer cells
has the potential to uncover biochemical mechanisms that
support tumorigenesis and identify new drug targets. The
serine hydrolase KIAA1363 has been found to be highly
elevated in aggressive cancer cells from multiple tumors of
origin, where it plays a role in ether lipid metabolism.
Attempts to further characterizeKIAA1363 function incancer
have, however, been thwarted by a lack of pharmacological
tools to study this enzyme. Here, we have addressed this
challenge by creating a potent, selective, and in vivo–active
inhibitor of KIAA1363. Key to the development of this
compound (termed JW480) was the use of competitive
activity-based profiling assays to simultaneously refine
potency for KIAA1363 and selectivity across the larger serine
hydrolase class. JW480 reduces monoalkylglycerol ether
levels in androgen-independent prostate cancer cells and
impairs their migration, invasion, survival, and in vivo tumor
growth. These studies thus support a pro-tumorigenic func-
tion for KIAA1363 and report a versatile inhibitor for pharma-
cological characterization of this enzyme in living systems.482 Chemistry & Biology 18, 476–484, April 22, 2011 ª2011 ElsevierEXPERIMENTAL PROCEDURES
Preparation of Mouse Tissue Proteomes
Tissues were Dounce-homogenized in PBS (pH 7.4), followed by a low-speed
spin (1400 g for 5 min) to remove debris. The supernatant was then subjected
to centrifugation (100,000 3 g, 45 min) to provide the cytosolic fraction in the
supernatant and the unsoluble fraction as a pellet. The pellet was washed and
resuspended in PBS buffer by sonication. Total protein concentration in each
fraction was determined using a protein assay kit (Bio-Rad). Samples were
stored at 80C until use.
Inhibitor Treatments of Cells
Inhibitors were dissolved in DMSO and diluted into media or buffer prior to cell
or proteome treatment, respectively. For in vitro treatment, final DMSO
concentration was 4%. For in situ treatments of cells for ABPP, lipid measure-
ments, migration, cell-survival, and invasion assays, 23 106 cells were seeded
in 6 cm dishes (100% confluency) 24 hr prior to inhibitor pretreatment (in
DMSO at 0.1% final concentration) in serum-free media (3 ml) for the desig-
nated time before harvesting cells for ABPP or lipid measurements or before
the initiation of migration, cell-survival, and invasion assays.
2-Acetyl MAGE Hydrolytic Activity Assays
Cells were pretreated with KIAA1363 inhibitors in situ (for 4 hr in serum-free
F-12K media before harvesting cells by scraping) or in vitro (for 30 min at
37C in PBS) before addition of 2-acetyl MAGE (100 mM) to cell lysates at
room temperature for 30 min in a volume of 200 ml. Reactions were quenched
with 600 mL 2:1 chloroform:methanol, and 10 nmol of C12:0 MAGE internal
standard was added. The organic layer was extracted and 30 ml was injected
into an Agilent 1100-MSD LC-MS. LC-MS settings were as previously
described (Chiang et al., 2006). Product levels (C16:0 MAGE) were quantified
in relation to the internal standard. Specific activity was determined during the
linear phase of enzymatic reactions (i.e., less than 20% substrate utilized).
AChE Activity Assays
AChE activity was measured using a method similar to that described previ-
ously (Ellman et al., 1961). Briefly, 50 ml of 10 mM acetylthiocholine was added
to 200 ml of PBS containing 2mMDTNB and 20 mg of cell lysate or mouse brain
membrane proteome. Absorbance was measured at 412 nm over 5 min, and
the rate of product accumulation was calculated from the slope of the absor-
bance over time. For assays involving preincubation with inhibitors, the reac-
tions were prepared without acetylthiocholine and JW480 was incubated at
the indicated concentration for 30 min at 37C. Acetylthiocholine was then
added and the assay was performed exactly as described above.
Competitive ABPP Experiments
For ABPP experiments, cell lysate and tissue proteomes were treated with
1 mM FP-rhodamine for 30 min at room temperature (50 ml total reactionLtd All rights reserved
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Selective Inhibitor for Cancer Hydrolase KIAA1363volume) as described previously (Nomura et al., 2010). Reactions were
quenched with one volume of standard 43 SDS/PAGE loading buffer
(reducing), separated by SDS/PAGE (10% acrylamide), and visualized in-gel
with a Hitachi FMBio IIe flatbed fluorescence scanner (MiraiBio). Inhibitors
were preincubated prior (30 min or 4 hr at 37C in vitro or in situ, respectively)
to the addition of FP-rhodamine.
Competitive ABPP-MudPIT Analysis of Serine Hydrolase Activities
in Proteomes
Competitive ABPP-MudPIT experiments were performed as previously
described (Nomura et al., 2010). Briefly, 1 mg of proteome was labeled with
5 mM FP-biotin, followed by solubilization with 1% Triton X-100, denaturation
by SDS and heating, avidin precipitation of labeled proteins, and on-bead
tryptic digest. Tryptic peptides were then loaded on to a biphasic (strong
cation exchange/reverse phase) capillary column and analyzed by two-dimen-
sional liquid chromatography (2D-LC) separation in combination with tandem
mass spectrometry using an Agilent 1100 LC system coupled with a Thermo-
Fisher LTQ linear ion trap mass spectrometer. Spectral counts are reported as
the average of three samples with the standard error of the mean (SEM).
Generation of KIAA1363 Knockdown Cells
Stable knockdown of KIAA1363 in PC3 cells was achieved using a targeted
short-hairpin oligonucleotide described previously (Chiang et al., 2006).
Cell Migration, Cell Survival, and Invasion Studies
Cell migration, cell survival, and invasion studies were performed as previously
described (Nomura et al., 2010). Briefly, migration assays were performed in
Transwell chambers (Corning) with 8 mm pore-sized membranes coated with
10 mg/ml collagen at 37C for LNCaP (24 hr), PC3 (4 hr), and DU145 cells
(24 hr), respectively. Cell survival assays were performed using the Cell Prolif-
eration ReagentWST-1 (Roche) Invasion assays were conducted using the BD
Matrigel Invasion Chambers per the manufacturer’s protocol. Inhibitors were
preincubated for the stated duration before seeding cells into migration,
cell-survival, or invasion chambers. Prior to seeding the cells in these cham-
bers, cells were serum-starved for 4 hr. Inhibitors were also present during
the migration, cell-survival, and invasion assays.
In Vivo Studies with JW480
JW480was administered by oral gavage (in PEG300, 4 ml/g mouse) or intraper-
itoneally (in 18:1:1 v/v/v solution of saline:ethanol:emulphor, 10 ml/g). After the
indicated amount of time, mice were anesthetized with isoflurane and killed by
decapitation. Tissues were removed and then flash frozen in liquid N2. Tissues
were stored at80C until use. Animal experiments were conducted in accor-
dance with the guidelines of the institutional Animal Care and Use Committee
of The Scripps Research Institute.
Tumor Xenograft Studies
Human cancer xenografts were established by transplanting cancer cell lines
ectopically into the flank of C.B17 SCID mice (Taconic Farms). Briefly, cells
were washed two times with PBS, trypsinized, and harvested in serum-
containing medium. Next, the harvested cells were washed two times with
serum-free medium and resuspended at a concentration of 2.0 3 104 cells/ml
and 100 ml was injected. Growth of the tumors was measured every 3 days
with calipers. For chronic JW480 treatment studies, mice were treated with
JW480 or vehicle once daily (at approximately the same time everyday) by
oral gavage in PEG300 (4 ml/g mouse). The treatments were initiated immedi-
ately after ectopic injection of cancer cells.
Lipid Measurements in Cancer Cells
Lipid measurements were performed in cancer cells as previously described
(Chiang et al., 2006). Briefly, frozen cell pellets from cells harvested after 4 hr
serum starvation were extracted in 2:1:1 chloroform:methanol:Tris buffer (pH
8.0) by Dounce homogenization with 10 nmol of internal standard C12
MAGE. The organic layer was removed, dried under N2, and resuspended in
120 ml of chloroform, and 30 ml was injected into an Agilent 1100-MSD
LC-MS. MAGE levels were quantified by measuring the area under the peak
and were normalized to the C12 MAGE internal standard.Chemistry & Biology 18,SUPPLEMENTAL INFORMATION
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